Lidocain Aguettant

Lidocaine, the active ingredient in Lidocain Aguettant, is a local anesthetic presented as a solution for injection for infiltration, intradermal and intravenous use. It provides reversible loss of sensation for minor surgical, dental and cardiac procedures in adult patients. GNH USA supplies Lidocain Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is a local anesthetic that blocks nerve conduction in various clinical settings. - Minor surgical procedures: provides rapid, reversible local anesthesia for skin and soft‑tissue surgery. - Dental procedures: numbs oral tissues to facilitate extractions, restorations and periodontal work. - Intravenous antiarrhythmic use: stabilises cardiac rhythm in selected arrhythmias under monitored conditions.

Lidocaine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Burning or stinging at the injection site - Tingling or numbness extending beyond the target area - Dizziness or light‑headedness - Nausea or metallic taste in the mouth

Serious or Rare Side Effects: - Seizures or convulsions - Cardiac arrhythmias, including ventricular tachycardia - Severe allergic reactions such as anaphylaxis - Methemoglobinemia leading to cyanosis - Respiratory depression or arrest

When using Lidocain Aguettant, consider the following safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Dose minimisation: employ the lowest effective concentration for the intended procedure. - Cardiac monitoring: observe heart rate and rhythm, especially for intravenous use. - Hepatic function: exercise caution in patients with severe liver disease due to altered metabolism. - Neurological conditions: avoid or reduce dose in individuals with epilepsy or seizure disorders. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Lidocaine can interact with several medicines, altering its safety or efficacy.

Major Interactions (Avoid): - Quinidine: may increase plasma lidocaine levels and toxicity. - Beta‑blockers: combined use can enhance cardiac depressant effects. - Other amide‑type local anesthetics: concurrent administration raises risk of systemic toxicity.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may potentiate central nervous system effects. - Diuretics (e.g., furosemide): can reduce plasma protein binding, increasing free lidocaine. - Cimetidine: may inhibit hepatic metabolism, modestly raising lidocaine concentrations.